Personalized ß-lactam dosing in patients with coronavirus disease 2019 (COVID-19) and pneumonia: a retrospective analysis on pharmacokinetics and pharmacokinetic target attainment
Pathophysiological changes are important risk factors for critically ill patients with pneumonia manifesting sub-therapeutic antibiotic exposures during empirical treatment. The effect of coronavirus disease 2019 (COVID-19) on antibiotic dosing requirements is uncertain. We aimed to determine the ef...
Gespeichert in:
| Hauptverfasser: | , , , , , , , |
|---|---|
| Dokumenttyp: | Article (Journal) |
| Sprache: | Englisch |
| Veröffentlicht: |
2021
|
| In: |
Medicine
Year: 2021, Jahrgang: 100, Heft: 22, Pages: 1-7 |
| ISSN: | 1536-5964 |
| DOI: | 10.1097/MD.0000000000026253 |
| Online-Zugang: | Verlag, lizenzpflichtig, Volltext: https://doi.org/10.1097/MD.0000000000026253 Verlag, lizenzpflichtig, Volltext: https://journals.lww.com/md-journal/Fulltext/2021/06040/Personalized___lactam_dosing_in_patients_with.98.aspx 
|
| Verfasserangaben: | Ute Chiriac, Otto R. Frey, Anka C. Roehr, Andreas Koeberer, Patrick Gronau, Thomas Fuchs, Jason A. Roberts, Alexander Brinkmann |
MARC
| LEADER | 00000caa a2200000 c 4500 | ||
|---|---|---|---|
| 001 | 1764964349 | ||
| 003 | DE-627 | ||
| 005 | 20230428014747.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 210730s2021 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1097/MD.0000000000026253 |2 doi | |
| 035 | |a (DE-627)1764964349 | ||
| 035 | |a (DE-599)KXP1764964349 | ||
| 035 | |a (OCoLC)1341419925 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rda | ||
| 041 | |a eng | ||
| 084 | |a 33 |2 sdnb | ||
| 100 | 1 | |a Chiriac, Ute |e VerfasserIn |0 (DE-588)1196234787 |0 (DE-627)1678100854 |4 aut | |
| 245 | 1 | 0 | |a Personalized ß-lactam dosing in patients with coronavirus disease 2019 (COVID-19) and pneumonia |b a retrospective analysis on pharmacokinetics and pharmacokinetic target attainment |c Ute Chiriac, Otto R. Frey, Anka C. Roehr, Andreas Koeberer, Patrick Gronau, Thomas Fuchs, Jason A. Roberts, Alexander Brinkmann |
| 246 | 3 | 3 | |a Personalized beta-lactam dosing in patients with coronavirus disease 2019 (COVID-19) and pneumonia |
| 264 | 1 | |c 2021 | |
| 300 | |a 7 | ||
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Gesehen am 30.07.2021 | ||
| 520 | |a Pathophysiological changes are important risk factors for critically ill patients with pneumonia manifesting sub-therapeutic antibiotic exposures during empirical treatment. The effect of coronavirus disease 2019 (COVID-19) on antibiotic dosing requirements is uncertain. We aimed to determine the effect of COVID-19 on ß-lactam pharmacokinetics (PK) and PK target attainment in critically ill patients with a personalized dosing strategy. - Retrospective, single-center analysis of COVID-19 ± critically ill patients with pneumonia (community-acquired pneumonia or hospital-acquired pneumonia) who received continuous infusion of a ß-lactam antibiotic with dosing personalized through dosing software and therapeutic drug monitoring. A therapeutic exposure was defined as serum concentration between (css) 4 to 8 times the EUCAST non-species related breakpoint). - Data from 58 patients with pneumonia was analyzed. Nineteen patients were tested COVID-19-positive before the start of the antibiotic therapy for community-acquired pneumonia or hospital-acquired pneumonia. Therapeutic exposure was achieved in 71% of COVID-19 patients (68% considering all patients). All patients demonstrated css above the non-species-related breakpoint. Twenty percent exceeded css above the target range (24% of all patients). The median ß-lactam clearance was 49% compared to ß-lactam clearance in a standard patient without a significant difference regarding antibiotic, time of sampling or present COVID-19 infection. Median daily doses were 50% lower compared to standard bolus dosing. - COVID-19 did not significantly affect ß-lactam pharmacokinetics in critically ill patients. Personalized ß-lactam dosing strategies were safe in critically ill patients and lead to high PK target attainment with less resources. | ||
| 700 | 1 | |a Frey, Otto R. |e VerfasserIn |4 aut | |
| 700 | 1 | |a Roehr, Anka C. |e VerfasserIn |4 aut | |
| 700 | 1 | |a Koeberer, Andreas |e VerfasserIn |4 aut | |
| 700 | 1 | |a Gronau, Patrick |e VerfasserIn |4 aut | |
| 700 | 1 | |a Fuchs, Thomas |e VerfasserIn |4 aut | |
| 700 | 1 | |a Roberts, Jason A. |e VerfasserIn |4 aut | |
| 700 | 1 | |a Brinkmann, Alexander |e VerfasserIn |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Medicine |d Baltimore, Md. : Lippincott Williams & Wilkins, 1922 |g 100(2021), 22, Artikel-ID e26253, Seite 1-7 |h Online-Ressource |w (DE-627)330613820 |w (DE-600)2049818-4 |w (DE-576)096290811 |x 1536-5964 |7 nnas |a Personalized ß-lactam dosing in patients with coronavirus disease 2019 (COVID-19) and pneumonia a retrospective analysis on pharmacokinetics and pharmacokinetic target attainment |
| 773 | 1 | 8 | |g volume:100 |g year:2021 |g number:22 |g elocationid:e26253 |g pages:1-7 |g extent:7 |a Personalized ß-lactam dosing in patients with coronavirus disease 2019 (COVID-19) and pneumonia a retrospective analysis on pharmacokinetics and pharmacokinetic target attainment |
| 856 | 4 | 0 | |u https://doi.org/10.1097/MD.0000000000026253 |x Verlag |x Resolving-System |z lizenzpflichtig |3 Volltext |
| 856 | 4 | 0 | |u https://journals.lww.com/md-journal/Fulltext/2021/06040/Personalized___lactam_dosing_in_patients_with.98.aspx |x Verlag |z lizenzpflichtig |3 Volltext |
| 951 | |a AR | ||
| 992 | |a 20210730 | ||
| 993 | |a Article | ||
| 994 | |a 2021 | ||
| 998 | |g 1196234787 |a Chiriac, Ute |m 1196234787:Chiriac, Ute |d 140000 |e 140000PC1196234787 |k 0/140000/ |p 1 |x j | ||
| 999 | |a KXP-PPN1764964349 |e 3958613497 | ||
| BIB | |a Y | ||
| SER | |a journal | ||
| JSO | |a {"type":{"media":"Online-Ressource","bibl":"article-journal"},"note":["Gesehen am 30.07.2021"],"recId":"1764964349","name":{"displayForm":["Ute Chiriac, Otto R. Frey, Anka C. Roehr, Andreas Koeberer, Patrick Gronau, Thomas Fuchs, Jason A. Roberts, Alexander Brinkmann"]},"id":{"eki":["1764964349"],"doi":["10.1097/MD.0000000000026253"]},"physDesc":[{"extent":"7 S."}],"origin":[{"dateIssuedKey":"2021","dateIssuedDisp":"2021"}],"titleAlt":[{"title":"Personalized beta-lactam dosing in patients with coronavirus disease 2019 (COVID-19) and pneumonia"}],"relHost":[{"id":{"zdb":["2049818-4"],"eki":["330613820"],"issn":["1536-5964"]},"type":{"media":"Online-Ressource","bibl":"periodical"},"pubHistory":["1.1922 -"],"note":["Gesehen am 26.11.20"],"part":{"issue":"22","volume":"100","pages":"1-7","extent":"7","year":"2021","text":"100(2021), 22, Artikel-ID e26253, Seite 1-7"},"recId":"330613820","disp":"Personalized ß-lactam dosing in patients with coronavirus disease 2019 (COVID-19) and pneumonia a retrospective analysis on pharmacokinetics and pharmacokinetic target attainmentMedicine","language":["eng"],"origin":[{"dateIssuedDisp":"1922-","publisher":"Lippincott Williams & Wilkins","dateIssuedKey":"1922","publisherPlace":"Baltimore, Md."}],"physDesc":[{"extent":"Online-Ressource"}],"title":[{"title_sort":"Medicine","title":"Medicine"}]}],"person":[{"role":"aut","roleDisplay":"VerfasserIn","given":"Ute","display":"Chiriac, Ute","family":"Chiriac"},{"family":"Frey","given":"Otto R.","role":"aut","roleDisplay":"VerfasserIn","display":"Frey, Otto R."},{"family":"Roehr","display":"Roehr, Anka C.","given":"Anka C.","role":"aut","roleDisplay":"VerfasserIn"},{"family":"Koeberer","given":"Andreas","role":"aut","roleDisplay":"VerfasserIn","display":"Koeberer, Andreas"},{"display":"Gronau, Patrick","roleDisplay":"VerfasserIn","role":"aut","given":"Patrick","family":"Gronau"},{"family":"Fuchs","display":"Fuchs, Thomas","given":"Thomas","role":"aut","roleDisplay":"VerfasserIn"},{"family":"Roberts","role":"aut","roleDisplay":"VerfasserIn","given":"Jason A.","display":"Roberts, Jason A."},{"roleDisplay":"VerfasserIn","role":"aut","given":"Alexander","display":"Brinkmann, Alexander","family":"Brinkmann"}],"language":["eng"],"title":[{"subtitle":"a retrospective analysis on pharmacokinetics and pharmacokinetic target attainment","title_sort":"Personalized ß-lactam dosing in patients with coronavirus disease 2019 (COVID-19) and pneumonia","title":"Personalized ß-lactam dosing in patients with coronavirus disease 2019 (COVID-19) and pneumonia"}]} | ||
| SRT | |a CHIRIACUTEPERSONALIZ2021 | ||